BCL2A1 and breast carcinoma: NCOA3-specific inhibitors, such as bufalin and gossypol, block NCOA3 function, thereby negatively affecting the function of the NCOA3-p300-NF-κB complex and consequently decreasing the expression of BCL2, BCL2A1, BCL2L2, and MCL1. Downregulation of these antiapoptotic genes then promotes apoptosis and inhibits breast cancer cell growth (Fig. 8B).